Display options
Cite
Fernández-Guasti A, Ulloa RE, Nicolini H. Age differences in the sensitivity to clomipramine in an animal model of obsessive-compulsive disorder. Psychopharmacology (Berl). 2003;166(3):195-201doi: 10.1007/s00213-002-1301-1.
Fernández-Guasti, A., Ulloa, R. E., & Nicolini, H. (2003). Age differences in the sensitivity to clomipramine in an animal model of obsessive-compulsive disorder. Psychopharmacology, 166(3), 195-201. https://doi.org/10.1007/s00213-002-1301-1
Fernández-Guasti, A, et al. "Age differences in the sensitivity to clomipramine in an animal model of obsessive-compulsive disorder." Psychopharmacology vol. 166,3 (2003): 195-201. doi: https://doi.org/10.1007/s00213-002-1301-1
Fernández-Guasti A, Ulloa RE, Nicolini H. Age differences in the sensitivity to clomipramine in an animal model of obsessive-compulsive disorder. Psychopharmacology (Berl). 2003 Mar;166(3):195-201. doi: 10.1007/s00213-002-1301-1. Epub 2003 Feb 13. PMID: 12589517.
Copy Download .nbib Format: NLM
Share it on

Psychopharmacology (Berl). 2003 Mar;166(3):195-201. doi: 10.1007/s00213-002-1301-1. Epub 2003 Feb 13.

Age differences in the sensitivity to clomipramine in an animal model of obsessive-compulsive disorder.

Psychopharmacology

A Fernández-Guasti, R E Ulloa, H Nicolini

Affiliations

  1. Departamento de Farmacobiología, Centro de Investigación y Estudios Avanzados, Calz. De los Tenorios 235, Col. Granjas Coapa, 14330, México D.F., México. [email protected]

PMID: 12589517 DOI: 10.1007/s00213-002-1301-1

Abstract

RATIONALE: Subtypes of obsessive-compulsive disorder (OCD) related to age could determine differential response to treatment.

OBJECTIVES: To explore possible age differences in the effect of clomipramine in an animal model of OCD.

METHODS: The deficits on spontaneous alternation produced by 8-OH-DPAT and the preventing actions of clomipramine, desipramine and WAY 100635 were compared between young and adult rats.

RESULTS: No age differences were found in spontaneous alternation. The 5-HT(1A) agonist, 8-OH-DPAT (0.031, 0.125, 0.5 and 2.0 mg/kg, -15 min) produced perseveration in young and adult rats. However, young rats were sensitive to a lower dose of 8-OH-DPAT. Clomipramine (10 mg/kg per three administrations) completely prevented the action of 8-OH-DPAT (0.5 mg/kg) in adult rats. However, this treatment as well as higher doses (15 mg/kg 3 administrations) or injected for longer periods (10 mg/kg 5 administrations) produced weak protective effects (versus 0.125 mg/kg 8-OH-DPAT) or had no action (versus 0.5 mg/kg 8-OH-DPAT) in young animals. WAY 100 635 (0.5 mg/kg) blocked the action of 8-OH-DPAT (0.5 mg/kg) in both young and adult rats. Desipramine (10 mg/kg/3 administrations) lacked of a preventive effect on the 8-OH-DPAT (0.5 mg/kg) action. This result indicated that the 5-HT(1A) receptor is involved in the deficits on spontaneous alternation produced by 8-OH-DPAT.

CONCLUSIONS: The present data shows important age differences in the effect of clomipramine in a model of OCD. Such differences could be relevant for the age variations in the response to treatment in clinical practice.

References

  1. Arch Gen Psychiatry. 2000 Jan;57(1):76-82 - PubMed
  2. Neuropharmacology. 1989 Jun;28(6):635-42 - PubMed
  3. Pharmacol Biochem Behav. 1991 Oct;40(2):311-5 - PubMed
  4. J Pharmacol Exp Ther. 1983 May;225(2):387-90 - PubMed
  5. J Chem Neuroanat. 1997 Jun;13(1):53-61 - PubMed
  6. Jpn J Pharmacol. 2001 Aug;86(4):451-3 - PubMed
  7. Neuroscience. 1999 Mar;89(3):743-9 - PubMed
  8. Brain Res Dev Brain Res. 2000 Jan 3;119(1):33-45 - PubMed
  9. Exp Clin Psychopharmacol. 1997 May;5(2):107-12 - PubMed
  10. Neuropharmacology. 2000 Sep;39(12):2309-17 - PubMed
  11. Neuropharmacology. 1994 Mar-Apr;33(3-4):275-317 - PubMed
  12. Dev Psychobiol. 1999 Mar;34(2):109-17 - PubMed
  13. Br J Psychiatry. 1994 Apr;164(4):459-68 - PubMed
  14. Psychopharmacology (Berl). 1984;83(1):1-16 - PubMed
  15. Arch Gen Psychiatry. 1989 Dec;46(12):1088-92 - PubMed
  16. Int J Neuropsychopharmacol. 2001 Jun;4(2):169-78 - PubMed
  17. J Pharmacol Exp Ther. 1999 Jan;288(1):81-7 - PubMed
  18. Physiol Behav. 1995 Jan;57(1):55-9 - PubMed
  19. Brain Res. 1989 Jun 26;490(2):255-67 - PubMed
  20. J Clin Psychiatry. 1990 Jul;51(7):292-7 - PubMed
  21. Child Adolesc Psychiatr Clin N Am. 1999 Jul;8(3):617-34, x - PubMed
  22. Eur J Pharmacol. 1990 May 16;180(2-3):305-9 - PubMed
  23. J Am Acad Child Adolesc Psychiatry. 1998 Apr;37(4):420-7 - PubMed
  24. J Clin Psychopharmacol. 1990 Apr;10(2):122-4 - PubMed
  25. Child Adolesc Psychiatr Clin N Am. 1999 Jul;8(3):533-75, ix - PubMed
  26. Int Clin Psychopharmacol. 1996 Mar;11(1):37-44 - PubMed
  27. J Psychopharmacol. 2001 Sep;15(3):173-9 - PubMed
  28. Eur J Pharmacol. 1993 Mar 30;234(1):29-34 - PubMed
  29. Neuropsychobiology. 2001;44(2):78-83 - PubMed
  30. Behav Neurosci. 1998 Dec;112(6):1475-85 - PubMed
  31. Psychopharmacology (Berl). 1988;95(2):167-70 - PubMed
  32. Int J Neuropsychopharmacol. 2001 Sep;4(3):269-72 - PubMed
  33. Behav Pharmacol. 1998 Nov;9(7):509-19 - PubMed
  34. Am J Psychiatry. 2001 Nov;158(11):1899-903 - PubMed
  35. J Clin Psychiatry. 1999 Feb;60(2):101-6 - PubMed
  36. Nihon Yakurigaku Zasshi. 1994 Jul;104(1):39-49 - PubMed
  37. J Pharmacol Exp Ther. 1999 Jan;288(1):247-53 - PubMed
  38. Eur Psychiatry. 1999 Dec;14(8):434-41 - PubMed
  39. J Clin Psychiatry. 1997;58 Suppl 12:18-22 - PubMed
  40. Neuropharmacology. 1994 Mar-Apr;33(3-4):325-30 - PubMed
  41. Eur J Pharmacol. 1988 Jul 7;151(2):267-73 - PubMed
  42. Clin Pharmacol Ther. 1982 Mar;31(3):393-401 - PubMed
  43. Ann N Y Acad Sci. 1995 May 10;757:245-52 - PubMed

Substances

MeSH terms

Publication Types